CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This research study is evaluating a combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic...
Phase 1
Durham, North Carolina, United States and 3 other locations
new drug called ibrutinib in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR) as a possible treatment for Chronic...
Phase 2
Durham, North Carolina, United States and 8 other locations
This study will help researchers collect more information about how effective the combination of venetoclax and obinutuzumab is in treating CLL in pe...
Phase 2
Chapel Hill, North Carolina, United States and 7 other locations
patient populations.CAP-100 is expected to prevent the migration of leukemia cells to and their survival in lymphoid niches as well as to el...
Phase 1
Durham, North Carolina, United States and 5 other locations
Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia...
Phase 2
Durham, North Carolina, United States and 7 other locations
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...
Phase 3
Durham, North Carolina, United States and 130 other locations
Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia...
Phase 3
Durham, North Carolina, United States and 83 other locations
objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...
Phase 3
Durham, North Carolina, United States and 230 other locations
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...
Phase 1, Phase 2
Durham, North Carolina, United States and 79 other locations
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...
Phase 3
Durham, North Carolina, United States and 216 other locations
Clinical trials
Research sites
Resources
Legal